

This communication should be viewed by:

Primary Care Providers, Behavioral Health Providers, Clinical staff, Claims and Billing Department

Pharmacy Policy Updates Effective January 1, 2026

MVP Health Care® (MVP) appreciates the work that you do to support our Members.

To view all current MVP Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes** – Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective January 1, 2026, and will be available for viewing on or before December 1, 2025. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Effective November 1, 2025	
Gaucher Disease Type 1 Treatment	Updated
Vimseltinib (Romvimza)	New
Effective January 1, 2026	
Abatacept	No changes
Abatacept Part B	No changes
ACL Inhibitors	No changes
Adalimumab (Humira)	No changes
Apremilast (Otezla)	No changes
Tadalafil for BPH (formerly Cialis for BPH)	Updated
Etanercept (Enbrel)	Updated
Formulary Exception For Non- Covered Drugs (External)	No changes
Golimumab	No changes
Golimumab Part B	No changes
Gout Treatments	No changes
Infliximab	No changes
Infliximab Part B	No changes
Irritable Bowel Syndrome	Updated
Methotrexate Autoinjector	Updated
MVP Cancer Guidance Program	Updated
Pain Medications	Updated
PCSK9 Inhibitors	Updated
Proton Pump Inhibitor Therapy	No changes
Transgender Hormone Therapy (Commercial, Exchange, Child Health Plus)	No changes
Vyepti (formerly CGRP)	Updated
Vypetic Medicare Part B (formerly CGRP Agents Part B)	Updated
Weight loss Medications	Updated